A phase I/II trial of perioperative paclitaxel (P), carboplatin (C), and erlotinib (E) with concurrent accelerated hyperfractionated radiation (HFRT) followed by maintenance E for stage III non-small cell lung cancer (NSCLC)

Nathan A. Pennell,Gregory M.M. Videtic,Sudish C. Murthy,David P. Mason,Thomas W. Rice,Peter J. Mazzone,Julia Samsa,T. Rich,Marc A. Shapiro,Tarek Mekhail

A phase I/II trial of perioperative paclitaxel (P), carboplatin (C), and erlotinib (E) with concurrent accelerated hyperfractionated radiation (HFRT) followed by maintenance E for stage III non-small cell lung cancer (NSCLC)

2016

Nathan A. Pennell
Gregory M.M. Videtic
Sudish C. Murthy
David P. Mason
Thomas W. Rice
Peter J. Mazzone
Julia Samsa
T. Rich
Marc A. Shapiro
Tarek Mekhail

7557 Background: Concurrent chemoradiotherapy (CRT) is standard treatment for stage III NSCLC, although the management of resectable patients (pts) remains controversial. We report an open-label ph...

Keywords:

Standard treatment
Internal medicine
Stage III Non-Small Cell Lung Cancer
Oncology
Erlotinib
Paclitaxel
Chemoradiotherapy
Pathology
Carboplatin
Hyperfractionated Radiation
Medicine
Perioperative
phase i ii

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations